Artemis Proximal Femoral Nail for Internal Fixation of Intertrochanteric Femur Fractures
Launched by JOHNS HOPKINS UNIVERSITY · Sep 26, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Artemis Proximal Femoral Nail for Internal Fixation of Intertrochanteric Femur Fractures" is studying a new device called the Artemis Proximal Femoral Nail (PFN). This device is designed to help fix fractures in the upper part of the thigh bone (femur) that occur near the hip. The goal of this pilot study is to see how safe and effective the Artemis PFN is compared to other existing treatments for these types of fractures. The trial is currently recruiting participants who are between the ages of 65 and 74 and have stable intertrochanteric fractures that need surgical treatment.
To be eligible for the study, patients must have had a non-pathologic fracture from trauma (meaning it wasn't caused by a disease) and need a specific type of nail fixation for their injury. Unfortunately, patients under 18 years old, pregnant women, or those with other significant bone injuries cannot participate. If you join the study, you can expect to receive treatment with the Artemis PFN and be monitored for its effectiveness and safety. This trial could help improve future treatments for hip fractures and assist many patients in recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients with traumatic, non-pathologic stable intertrochanteric fractures requiring cephalomedullary nail fixation
- Exclusion Criteria:
- • Pediatric patients (\<18 years)
- • Pregnant females
- • Patients with other concomitant orthopaedic injuries
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Amiethab Aiyer, MD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials